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Abstract
Objective—Overall, the clinical spectrum of depression during the perimenopause is not well
characterized. This cross-sectional study examined the following: 1) clinical characteristics of
women who presented to the NIMH midlife mood disorders clinic (between March 1990 and January
2004) with perimenopausal major and minor depressions; 2) the impact on these measures of either
a prior episode of depression or the presence of hot flushes.
Method—Historical variables, reproductive status, symptom ratings, and plasma hormone measures
were examined in 116 women who met research criteria for perimenopause-related depression (a
current episode of major or minor depression according to the Structured Clinical Interview for DSM-
IV or Primary Care Evaluation of Mental Disorders supplemented with a past history form).
Results—Clinical characteristics did not differ in those women with first onset (39%) versus
recurrent depressions or in those with (57%) and without hot flushes. Depressive episodes clustered
in the later stages of the menopause transition and the first year postmenopause. Seven (6%) women
reported a past postpartum major depression, and 55% of women reported a history of premenstrual
dysphoria (PMD).
Conclusions—We found no evidence that either hot flushes or a previous episode of depression
conveys a distinct clinical profile in these women. The clustering of onsets of depression suggests
that the hormone events that characterize the late menopause transition may be relevant to the onset
of this form of depression. Finally, although we observed a high rate of PMD, neither postpartum
depression nor PMD are consistent accompaniments of perimenopausal depression.
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Recent epidemiologic studies have documented an increased risk of first onset and recurrent
major and minor depressions during the menopause transition (MT) compared with the
premenopause.1–4 Several as yet untested hypotheses have been proposed to explain the onset
of depression in women during the MT. Depression could be caused by specific endocrine
events or physiologic concomitants (e.g., hot flushes) related to the MT. This would not explain,
however, why depression is triggered by these events in some women but not others.
Consequently, the onset of depression could reflect a vulnerability to develop recurrent
depression in women with a past depression or, in particular, those with a history of depression
during other periods of reproductive hormone change. The MT is a complex series of
physiologic events that lasts an average of five years and includes variations in endocrine
function that progress from increased estradiol secretion during the early MT, estrogen
withdrawal and finally hypogonadism during the perimenopause (i.e., late MT and first year
postmenopause). Additionally, in up to 80% of women, these endocrine events lead to hot
flushes5 that can disrupt sleep6 and, therefore, increase a woman’s risk of developing
depression.2 Thus, the timing of the onset of depression relative to the stages of the MT and
their associated endocrine events, or the symptomatic accompaniments of depression during
the perimenopause (i.e., hot flushes), if uniformly present, could suggest the relevance of these
factors in the onset of depression during the MT.
Historical variables in these women also may help identify factors contributing to the risk for
perimenopausal depression. Accompanying endocrine events or hot flushes might have more
of an impact in first (de novo) onset than recurrent forms of depression. However, studies have
not examined whether first onset depressions during the perimenopause are clinically distinct
from recurrent depressions. Similarly, although studies suggest that women with premenstrual
dysphoria (PMD) or postpartum depression (PPD) are at greater risk for depression during the
MT,7–9 the relevance of a history of PMD or PPD to a woman’s risk for depression during the
4 MT remains unclear.
This study is a preliminary effort to investigate whether a distinct clinical profile can be
identified that would suggest factors contributing to the onset of depression in perimenopausal
women. We address two questions about the clinical characteristics of perimenopausal major
and minor depressions. First, what is the clinical presentation of women who develop
depression during the perimenopause, including the stage of the MT (defined by the stages of
reproductive aging workshop (STRAW) criteria10) during which the depressions developed,
plasma levels of follicle stimulating hormone (FSH), the presence of hot flushes, the presence
of past depressive episodes (i.e., both non-reproductive- and reproductive-related mood
disorders), the severity of depression, and overall level of functional impairment? Second, do
these clinical characteristics or presenting symptomatologies of perimenopausal depression
differ when women are grouped by type of depression (major versus minor), past history of
depression, or presence of hot flushes?
Methods
Subject Selection
Participants were selected from 395 consecutive women between the ages of 40 and 55 years
attending the National Institute of Mental Health midlife mood disorders clinic [between March
1990 and January 2004]. Each woman reported the onset of depression associated with
menstrual irregularity (≥ six months but not > one year of amenorrhea); depressive symptoms,
by history, resulted in personal distress or occupational impairment. All women were either
self-referred in response to local advertisements or referred by their physicians. Of these 395
women, 116 also met the following criteria: 1) a current episode of major or minor depression
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(evaluated by Structured Clinical Interview for DSM-IV (SCID)11 (n = 112) or Primary Care
Evaluation of Mental Disorders (PRIME MD)12 supplemented with a past history form12;13
(n = 4); women presenting prior to 1996 were evaluated with the Structured Clinical Interview
for DSM-III-R14 supplemented by the minor depression module of the Scheduled for Affective
Disorders and Schizophrenia-Lifetime Version.15 [Complete SCID interviews were not
available in four women; however, PRIME MDs completed during their initial visit were
considered adequate for inclusion in the sample.]; 2) 3 FSH plasma levels ≥ 14 IU/L obtained
at biweekly visits during a six week screening. [Plasma FSH levels of 14 IU/L represent two
standard deviations above the mean values for the early follicular phase FSH levels in women
of reproductive age, consistent with the STRAW criteria;10] and 3) the absence of a current or
recent medical illness confirmed by medical history and laboratory tests including thyroid-
stimulating hormone. All women were medication-free (with the exception of four women on
stable thyroid replacement). The protocol was approved by the NIMH Intramural Research
Subpanel, and written informed consent to measure plasma hormone levels and mood
symptoms was obtained from each woman. Overall characteristics of the study sample are
included in Table 1.
Protocol
All women attended at least three screening visits over a six week interval. During the first
visit, participants completed a semi-structured interview that detailed presenting symptoms,
the duration and level of functional impairment associated with the depression, historical
variables including history of PMD, and the characteristics of the menstrual cycle irregularity
or amenorrhea. During subsequent visits, blood samples were obtained for the measurement
of FSH levels. Finally, on a daily basis for the duration of the screening, women completed
the Daily Rating Form (DRF),16 a 21-item self-report scale. The DRF rates the severity of
symptoms on a six point scale (1 = no symptoms and 6 = extreme symptoms) and was used to
confirm the presence of clinically significant hot flushes, operationally defined by an average
score of > 2 on the DRF (2 = minimal) during four weeks throughout the screening; and to
quantify the level of functional impairment in each woman (determined by the number of days
during four weeks throughout screening in which the women rated functional impairment > 2
(minimal)). Participants were instructed to use the severity scale as a composite of their hot
flush frequency and severity.
Outcome Measures
1. Demographics, Historical Variables, Symptom Ratings: At each clinic visit, we
administered the following rating scales: 1) the Beck Depression Inventory (BDI)17
(average scores and the number of women with scores of ≥ 16, a standard cut-off score
indicating clinically significant symptoms, 2) the Center for Epidemiologic Studies-
Depression Scale (CES-D)18 (mean scores), and 3) VAS symptom inventory rating
the severity (range: none to extreme) of 23 mood and behavioral symptoms
(previously described.14) including the following: inability to enjoy usual activities,
excessive worrying, increased appetite or cravings, weight gain, lack of energy,
frequent sleep disturbance, problems concentrating, irritability, avoidance of social
activities, early morning wakening, preoccupation with physical health, anxiety,
tearfulness, emotional numbness, experiencing unpleasant life events, mood
instability, emotional detachment, lack of motivation, depressed mood, feelings of
letting people down, feeling detached or unreal, mood fragility, and feelings of being
unable to cope.
2. Hormone Measures: FSH plasma levels were measured by AxSYM
radioimmunoassay (Abbott Laboratories, Abbot Park, Ill.). The mean and standard
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deviation of the serial FSH levels obtained during each visit were calculated for each
woman.
3. Stage of Reproductive Aging: All women were classified into one of four STRAW
stages (-3 through +1a) as follows: stage -3: regular menstrual cycles and one elevated
(> 2 SD) FSH levels; stage -2: regular menstrual cycles, but with variable cycle lengths
(> or < 7 days) and elevated plasma FSH levels; stage -1: at least two skipped cycles
as well as an interval of amenorrhea (≥ 60 days) and elevated plasma FSH levels; and
+1a: up to one year of amenorrhea and elevated FSH levels.10
Statistical Analysis
To address the first question of this study, we employed descriptive statistics to characterize
the clinical profile of women with perimenopause-related depression including plasma levels
of FSH, scores on BDI and CES-D, STRAW stage, presence or absence of hot flushes, history
of depressive illness, level of functional impairment, and demographics. To address the second
question, we examined whether the clinical profile of perimenopausal depression differs as a
function of type of depression (major versus minor), past history of depression, or presence of
hot flushes. Student’s t-tests with the Bonferroni adjustment were employed to compare
dimensional baseline demographic characteristics, symptom rating scores (i.e., BDI and CES-
D), and plasma FSH levels (mean and SD) across the groups described above. Chi square
analyses (or the Fisher exact test when appropriate) with the Yate’s correction were used to
compare categorical characteristics. Significant 2×4 Chi square analyses were explored with
repeated 2×2 comparisons with Bonferroni adjustment of the p values. Finally, a multinomial
model was used to examine differences in the numbers of women in each STRAW stage within
each of the following groups: major depression, minor depression, first onset depression,
recurrent depression, women with hot flushes, and women without hot flushes.
To examine differences in the pattern of presenting symptoms, a stepwise forward discriminant
function analysis (DFA) (NCSS, Kaysville, VT) was performed to compare the scores on the
23 item VAS symptom rating in the following groups: a) women with current major versus
those with minor depression, b) women with recurrent versus first onset major or minor
depression, and c) depressed perimenopausal women with versus those without significant hot
flushes. When significant differences were identified by DFA, a binomial test with a Z
approximation compared calculations of the observed and chance proportions predicted by the
DFA (one-tailed tests were employed for the binomial tests since we were interested only in
factors that correctly predicted group membership).
Results
Group Comparisons
Major vs. Minor Depression—Women with major and minor depression did not differ in
any measure, with the exception that compared to those with minor depression, women with
major depression had significantly higher BDI and CES-D scores, a significantly greater
proportion of BDI scores ≥ 16 (Chi square = 22.1, p < 0.001), and significantly greater
impairment (both number of days and maximum impairment rating score) (Table 2). The
majority of both major and minor depressions occurred during STRAW stage -1 (Figure 1A).
However, the proportion of women in stage -2 was significantly higher in women with minor
(n = 21) compared with women with major depression (n = 3) (Chi square = 12.3, df = 3, p =
0.006; Fisher exact test, p = 0.003, p < 0.008 with correction). In women with major depression,
multinomial analyses identified significantly increased numbers of women in stages -1 and
+1a compared with stages -2 and -3, with the greatest number in stage -1. In women with minor
depression the numbers in stages -1 and -2 were significantly greater than in -3 and +1a.
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The DFA identified significantly higher severity of two variables - lack of motivation (p =
0.003) and feelings of letting people down (guilt) (p = 0.009) - in women with major compared
with those with minor depression. The model identified by the DFA correctly predicted
membership in 64% of the group with major and in 69% of those with minor depression. Thus
the overall predictive rate for this model was 66.6% compared with the expected predicted rate
of 50.5% [binomial comparison, z = 5.4, p (one-tailed) < 0.002].
First-Onset versus Recurrent Depression—Women with recurrent major or minor
depressions did not differ from those with first-onset depressions in any clinical characteristic
measured (Table 2); nor did the number of women in each STRAW stage differ significantly
between women with first onset compared with those with recurrent depression. Multinomial
analysis (Figure 1B) of the numbers of women in each STRAW stage showed that in first onset
depression a significantly greater number of women were in stage -1 (compared with stages
-3, -2 and +1a). The number of women with recurrent depression also was greatest in stage -1
and, although to a lesser extent, greater in stage -2 and +1a.
Severity scores for the VAS symptom of mood instability distinguished women with first onset
(lower scores) from those with recurrent depression (DFA, p < 0.0001). The model identified
by the DFA correctly predicted membership in 34% of the first onset and 90% of the recurrent
depression group. The overall prediction rate, therefore, was 68% compared to the expected
prediction rate of 57% [binomial comparison, z = 2.4, p (one-tailed) =.008].
Depression with and without Hot Flushes—Women with and without hot flushes did
not differ significantly in any clinical characteristic, although there was a trend for the mean
± SD plasma FSH levels to be higher in women with hot flushes (71.3 ± 37.0 IU/L) compared
with those without hot flushes (58.2 ± 31.7 IU/L) (t = 2.0, df = 114, p =.048), which did not
remain significant after Bonferroni adjustment (Table 2). In women without hot flushes,
multinomial analysis (Figure 1C) showed a greater number of women in STRAW stages -1
and -2. Similarly, in women with hot flushes, a greater number of women were in stages -1
and +1a
The DFA identified significantly higher severity scores for the symptom of feeling emotionally
numb (p <.0001) in women with hot flushes. The model identified by the DFA correctly
predicted 42% of the women without hot flushes and 78% of the women with hot flushes. The
overall prediction rate was 62.3% compared to an expected prediction rate of 52.6% [binomial
comparison, z = 2.1, p (one-tailed) = 0.02].
Discussion
Many assumptions are made about the cause and characteristics of depression occurring during
the MT, but little is actually known. Our data and those of recent studies3;15;16 dispel several
prevalent myths about perimenopausal depression. First, a substantial number of women
presented to our clinic with first onset depression in the perimenopause, and many of these
women had no evidence of hot flushes accompanying their depressions. Thus the development
of depression during the perimenopause is not simply due to either the distressing consequences
of hot flushes or the coincidental occurrence of a recurrent mood disorder. Indeed, the clinical
characteristics of perimenopausal depression are not affected by whether the episode is first
onset or accompanied by hot flushes.
Second, all depressive episodes clustered in the later STRAW stages of the MT and the first-
year postmenopause. Thus, these findings and those of others3 suggest a possible role for
estradiol withdrawal and the recent onset of hypogonadism in the development of depressions
during the MT.
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Finally, PPD was not a prevalent antecedent to, nor consequently, a predictor of,
perimenopausal depression. In contrast, self reports of PMD were prevalent and described by
over half of the women in our sample. Nonetheless, even self-reported PMD was not uniformly
present in all women. These data demonstrate, therefore, the potential comorbidity in some but
certainly not all women between perimenopausal depression and other reproductive endocrine-
related mood disorders.
A substantial number (39%) of the women in this study presented with their first lifetime
episode of major or minor depression. Nonetheless, there were no significant differences in
either the symptomatic or hormonal accompaniments of first onset versus recurrent depression
during the perimenopause. Additionally, there were no distinct patterns of clustering of first
onset and recurrent depressions during any of the STRAW stages. These data are consistent
with previous studies demonstrating the efficacy of estradiol therapy in depressed
perimenopausal women regardless of a past history of depression.14
The majority (57%) but certainly not all women with perimenopausal depression reported hot
flushes. Indeed, the presence of hot flushes neither significantly differed in first onset compared
with recurrent depressions, nor significantly predicted symptom severity or functional
impairment. Similarly, the presence of hot flushes predicted neither a distinct profile of
presenting symptoms nor the clustering of depressive episodes during a specific STRAW stage.
Interestingly, measures of disturbed sleep and early morning wakening also did not distinguish
groups of women in this study. Thus, as with a past episode of depression, the presence of hot
flushes in perimenopausal depression is not associated with a distinguishing set of hormonal
or symptomatic accompaniments. Freeman et al.3 observed that the increased risk for first onset
depression during the perimenopause was independent of the presence of hot flushes. Previous
studies also have reported that perimenopausal depressed women with hot flushes are not
distinguished from those without by their therapeutic responses to either estradiol therapy or
selective serotonin reuptake inhibitors (SSRIs),14;17–24 their profiles of basal plasma hormone
levels (with the exception of plasma FSH levels,25), or their reports of negative life events.26
Thus although hot flushes are frequent occurrences in depressed perimenopausal women (as
they also are in non-depressed perimenopausal women), hot flushes are not necessary
accompaniments of depression.
The majority (55%) of women with perimenopause-related depression presented to our clinic
in the later stages of the MT (i.e., STRAW stage -1). Although the overall distribution across
STRAW stages was similar for the onset of major and minor depression, more women with
minor depression presented in STRAW stage -2, and, therefore, earlier in the transition than
did those with major depression. Thus it is possible that the non-significant difference in the
distributions across STRAW stages reflects that some women with minor depression presented
to our clinic earlier in the course of their depressions.
The cross-sectional design of our study, the reliance on retrospective reports of menstrual cycle
irregularity and amenorrhea, and the fact that STRAW staging was performed at the time of
presentation to our clinic, prevents us from precisely determining the specific STRAW stages
in which the onsets of depression occurred. Although the majority of women in our study
presented within 18 months following the onset of symptoms, it is possible that these self-
reports did not accurately reflect the actual onsets of depression. Thus, depression in this study
could have started much earlier than we have reported. Nonetheless, all women described the
onset of depression in association with menstrual cycle irregularity or amenorrhea –
characteristics of the later menopause transition. A more accurate assessment of the
relationship between reproductive aging and the onset of depression could be obtained by
performing a population-based study rather than a clinic-based study, which relies on women
presenting for treatment of a disorder. It is reassuring, however, that a similar pattern of
Steinberg et al. Page 6













clustering of clinically significant depressive symptoms during the late menopause transition
also was observed by Bromberger et al.1
We observed that neither a history of postpartum depression nor PMD was a uniform
antecedent of depression during the perimenopause. Previous retrospective studies3;7–9; 31;
32 have reported a greater than expected frequency of occurrence of other reproductive
endocrine-related mood disorders (i.e., PMD and PPD) in women with perimenopausal
depression. Based on these observations, PPD has been inferred to be a risk factor for or a
predictor of depression during the MT;3;7–9;27;28 however, in contrast to our study, previous
observations were based solely on self-reports and were not confirmed with structured
diagnostic interviews. In our sample of well-characterized women with perimenopausal
depression, the prevalence of a history of PPD meeting DSM-IV criteria was less than 10%,
comparable to reported prevalence rates of PPD in the general population.29–31
In contrast to the apparent lack of association between postpartum and perimenopausal
depression, we observed that a substantial number of women with perimenopausal depression
reported the prior experience of PMD. Previous studies have reported similar findings
suggesting a relationship between PMD and perimenopausal depression. In a longitudinal,
community-based study of women with no history of depression, Freeman et al.3 identified
that a retrospective self-report of PMD was a significant predictor of perimenopausal
depression (defined by high CES-D scores). In a cross sectional, clinic-based study, however,
Richards et al.16 observed the notable absence of either prospectively confirmed premenstrual-
related symptom cyclicity or PMD in the majority of perimenopausal depressed women,
although, as a caveat, Richards et al.21 did observe a higher than expected rate of menses-
related dysphoric symptoms in the women with perimenopausal depression compared with
asymptomatic controls. It remains to be determined in prospective longitudinal studies if an
episode of PPD or PMD places a woman at increased risk for developing depression during
the perimenopause. As suggested by Richards et al.16 and others,3;7–9;32;33 the co-morbidities
of postpartum, premenstrual and perimenopausal depressions could distinguish a subgroup of
women predisposed to reproductive endocrine-related mood disorders.
In this study, the onsets of depression in perimenopausal women clustered during the later
stages of the MT. Thus, the hormonal events that characterize the late MT should not be
excluded as potentially relevant in the onset of this form of depression. Future studies of this
condition should investigate the possible role of estradiol withdrawal and the onset of a
hypogonadal state in the development of depression in these women. Minor depressions
occurring during the MT are frequent events, are associated with significant impairment, and,
with few exceptions, the clinical presentation is indistinguishable from major depressions that
occur at this stage of life. Finally, although the presence of somatic symptoms such as hot
flushes in depressed perimenopausal women do not accompany a unique clinical presentation,
they still may have clinically important effects and could lead to a delay in diagnosis34;35 or
presage differential treatment response characteristics.36 Thus the clinical significance of
depression (even minor depression) accompanied by perimenopausal somatic symptoms
should not be dismissed as an “appropriate” reaction to the disturbing somatic symptoms.
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Numbers of depressed perimenopausal women in each STRAW stage were compared across
three groups: (1) women with major versus minor depression, (2) first onset versus recurrent
depression, and (3) women with and without hot flushes
Criteria for STRAW Stages:
Stage -3: regular menstrual cycles and one elevated (> 2 SD) FSH level; stage -2: regular
menstrual cycles, but with variable cycle lengths (> or < 7 days) and elevated plasma FSH
levels; stage -1: at least two skipped cycles as well as an interval of amenorrhea (≥ 60 days)
and elevated plasma FSH levels; and stage +1a: up to one year of amenorrhea and elevated
FSH levels. STRAW = Stages of Reproductive Aging Workshop.
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a - minor depression versus major depression stage -2 Chi square = 12.3, df = 3, p = 0.006;
post-hoc Fisher Exact test, p =.003
The distribution of women with and without hot flushes in each STRAW stage differed
significantly (Chi square = 9.3, df = 3, p =.03).
Individual uncorrected 2×2 Chi square analyses were significantly different between women
with and without hot flushes in several comparisons as follows: first, significantly more women
without hot flushes were in STRAW stage -2; second, significantly more women with hot
flushes were in STRAW stages -1 and +1a. However, none of the comparisons remained
significant when p values were adjusted for six comparisons.
Otherwise all comparisons p = NS
Within Group Comparisons (multinomial):
1) major depression - the number of women in stage -1 was significantly greater than numbers
in stages +1a -2, -3 (Z = 4.3–6.1 [range]; p =.003 – <.001 [range]); number of women in stage
+1a was significantly greater than number in stages -3 and -2, (Z = 2.7 (both comparisons), p
=.008)
minor depression - the number of women in stages -1 and -2 was significantly different than
numbers in stages -3 and +1a (Z = 2.3–6.3 [range]; p =.02 – <.001 [range]); whereas numbers
of women in stages -1 and -2 was not significantly different (p = 0.1)
2) First-onset depression - a significantly greater number of women were in STRAW stage -1
(comparisons with stages -3, -2 (Z = 3.1 and 4.6; p =.002 and <.001; respectively) and +1a (Z
= 1.6; p =.12 trend)
recurrent depression - the number of women with recurrent depression was greatest in STRAW
stage -1 (Z = 3.5–8.0 [range]; all comparisons p <.001) and, although to a lesser extent, greater
in STRAW stage -2 (comparisons with -3 (Z = 3.4; p =.008) and +1a (Z = 1.6; p =.11)
3) depression with hot flushes (HF) - greater numbers of women were in STRAW stages -1
(compared to +1a: Z = 3.8; p <.001, to -2: Z = 5.8; p <.001 and -3: Z = 8.7; p <.001), and stage
+1a (compared to -3: Z = 3.4; p <.001)
depression without hot flushes (HF) - a greater number of women were in STRAW stages -1
(compared to +1a: Z = 3.8; p =.001 and to -3: Z = 8.7; p <.001) and stage -2 (compared to -3:
Z = 2.9; p =.004 and to +1a: Z = 2.0; p =.052)
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Table 1
Demographic Characteristics of Women with Perimenopausal Depression (n = 116)
Perimenopausal
Age, Mean (SD), y 49.0 (3.4)
Smoking, N (%) 18 (15.5)
Currently Married, N (%) 73 (62.9)
Parity, Mean (SD) 1.6 (1.2)
Taking Thyroid Hormone, N (%) 4 (3.4)
a Plasma FSH (IU/L):
 Mean (SD) 65.6 (35.2)
 Standard Deviation, Mean (SD)b 19.7 (12.1)
Confirmed Hot Flushes, N (%) 66 (57.0)
STRAW CRITERIA, N (%):
 No. of Women in Stage -3 6 (5.0)
 No. of Women in Stage -2 24 (20.7)
 No. of Women in Stage -1 64 (55.2)
 No. of Women in Stage +1a 22 (19.0)
Current Major Depression, N (%) 50 (43.1)
 Duration mean (SD) 20.9 (11.7)
Current Minor Depression, N (%) 66 (57.0)
 Duration mean (SD) 19.4 (11.2)
First-Onset Depression, N (%) 45 (38.8)
Past Major Depression, N (%) 39 (33.6)
 Postpartum Onset, N (%) 7 (6.0)
Past Minor Depression, N (%) 32 (27.6)
 Postpartum Onset, N (%) 1 (0.9)
Premenstrual Dysphoria, N (%) 64 (55.2)
CES-D Score, Mean (SD) 22.6 (7.7)
BDI Score, Mean (SD) 14.7 (6.3)
a
Assays were performed in duplicate for all hormones and were repeated if the values differed by more than 15%. The inter-assay and intra-assay
coefficients of variation were calculated from the assays performed for each assessment period, with all coefficients being less than 5%.
b
The standard deviations of the serial FSH levels were calculated for each woman as a measure of the individual variability in FSH secretion.
Abbreviations: BDI = Beck Depression Inventory, CES-D = Center for Epidemiologic Studies-Depression Scale, FSH = follicle-stimulating hormone,
STRAW = Stages of Reproductive Aging Workshop.
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